Modification of gastric cancer risk associated with proton pump inhibitors by aspirin after  Helicobacter pylori  eradication

Ka Shing Cheung; Wai K. Leung

doi:10.18632/oncotarget.26382

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Modification of gastric cancer risk associated with proton pump inhibitors by aspirin after Helicobacter pylori eradication

Ka Shing Cheung and Wai K. Leung _

PDF | HTML | How to cite

Oncotarget. 2018; 9:36891-36893. https://doi.org/10.18632/oncotarget.26382

Metrics: PDF 1222 views | HTML 1853 views | ?

Abstract

Ka Shing Cheung1 and Wai K. Leung1

1 Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong

Correspondence to:

Wai K. Leung, email: [email protected]

Keywords: aspirin; PPI; H. pylori; gastric adenocarcinoma; triple therapy

Received: August 09, 2018 Accepted: October 23, 2018 Published: December 11, 2018

Abstract

Aim: Although proton pump inhibitors (PPIs) can prevent aspirin-induced upper gastrointestinal bleeding, a clinical dilemma exists as long-term use of PPI may also increase the risk of gastric cancer even after Helicobacter pylori (HP) eradication. We aimed to investigate the potential interaction between aspirin and PPIs on GC risk in patients who have HP eradicated.

Results: Of the 63,397 HP eradicated subjects (median follow-up 7.6 years), 153 (0.24%) developed GC. PPIs were associated with a higher GC risk among non-aspirin users (aHR: 3.73, 95% CI:2.11–6.60) but not among aspirin users (aHR: 0.35, 95% CI:0.04–2.74).

Materials and Methods: This is a post-hoc analysis based on a previously published territory-wide retrospective cohort study on the potential risk of PPIs on GC. Adults who had received an outpatient prescription of clarithromycin-based triple therapy for HP between 2003 and 2013 were identified. The adjusted hazard ratio (aHR) of GC with PPIs, stratified according to aspirin use, was calculated by Cox model with propensity score adjustment of other covariates.

Conclusions: The potential harmful effects of PPIs on GC development appear to be limited to non-aspirin users. Co-prescription of PPIs is therefore recommended for HP-eradicated patients who are at risk of aspirin-induced UGIB.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26382

Publication Alerts

Research Perspectives:

Modification of gastric cancer risk associated with proton pump inhibitors by aspirin after Helicobacter pylori eradication

Abstract